featured
Polatuzumab Vedotin in Relapsed/Refractory DLBCL
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Disclosure statements are available on the authors' profiles:
Journal of Clinical Oncology
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
Polatuzumab Vedotin in Relapsed or Refractory Diffuse Large B-Cell Lymphoma
J. Clin. Oncol 2019 Nov 06;[EPub Ahead of Print], LH Sehn, AF Herrera, CR Flowers, MK Kamdar, A McMillan, M Hertzberg, S Assouline, TM Kim, WS Kim, M Ozcan, J Hirata, E Penuel, JN Paulson, J Cheng, G Ku, MJ MatasarFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.